Unknown

Dataset Information

0

Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients.


ABSTRACT: Unrelated cord blood transplantation (UCBT) is an effective treatment for hematopoietic disorders. However, this attractive approach is frequently accompanied by pre-engraftment syndrome (PES), severe cases of PES are associated with enhanced mortality and morbidity, but the pathogenesis of PES remains unclear. Here we show that GM-CSF produced by cord blood-derived inflammatory monocytes drives PES pathology, and that monocytes are the main source of IL-6 during PES. Further, we report the outcome of a single arm, single-center clinical study of tocilizumab in the treatment of steroid-refractory severe PES patients (www.chictr.org.cn ChiCTR1800015472). The study met the primary outcome measure since none of the patients was nonrelapse death during the 100 days follow-up. The study also met key secondary outcomes measures of neutrophil engraftment and hematopoiesis. These findings offer a therapeutic strategy with which to tackle PES and improve nonrelapse mortality.

SUBMITTER: Jin L 

PROVIDER: S-EPMC8260612 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4237472 | biostudies-literature
| S-EPMC6481670 | biostudies-literature
| S-EPMC10653359 | biostudies-literature
| S-EPMC5665970 | biostudies-literature
| S-EPMC3955731 | biostudies-literature
| S-EPMC5959879 | biostudies-literature
| S-EPMC5831809 | biostudies-literature
2022-02-07 | GSE194334 | GEO
| S-EPMC3477519 | biostudies-literature
| S-EPMC7277103 | biostudies-literature